QURE vs. OPK, BCYC, IMNM, OCUL, ABVX, CVAC, CNTA, SPRY, PRTC, and ZNTL
Should you be buying uniQure stock or one of its competitors? The main competitors of uniQure include OPKO Health (OPK), Bicycle Therapeutics (BCYC), Immunome (IMNM), Ocular Therapeutix (OCUL), ABIVAX Société Anonyme (ABVX), CureVac (CVAC), Centessa Pharmaceuticals (CNTA), ARS Pharmaceuticals (SPRY), PureTech Health (PRTC), and Zentalis Pharmaceuticals (ZNTL). These companies are all part of the "pharmaceutical preparations" industry.
uniQure (NASDAQ:QURE) and OPKO Health (NASDAQ:OPK) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, earnings, institutional ownership, risk, analyst recommendations, media sentiment, profitability, valuation and dividends.
OPKO Health has higher revenue and earnings than uniQure. OPKO Health is trading at a lower price-to-earnings ratio than uniQure, indicating that it is currently the more affordable of the two stocks.
78.8% of uniQure shares are owned by institutional investors. Comparatively, 64.6% of OPKO Health shares are owned by institutional investors. 4.7% of uniQure shares are owned by insiders. Comparatively, 47.3% of OPKO Health shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
uniQure received 139 more outperform votes than OPKO Health when rated by MarketBeat users. Likewise, 70.70% of users gave uniQure an outperform vote while only 65.70% of users gave OPKO Health an outperform vote.
uniQure has a beta of 0.98, indicating that its stock price is 2% less volatile than the S&P 500. Comparatively, OPKO Health has a beta of 1.81, indicating that its stock price is 81% more volatile than the S&P 500.
In the previous week, OPKO Health had 7 more articles in the media than uniQure. MarketBeat recorded 9 mentions for OPKO Health and 2 mentions for uniQure. uniQure's average media sentiment score of 1.25 beat OPKO Health's score of 0.73 indicating that uniQure is being referred to more favorably in the media.
uniQure presently has a consensus price target of $24.75, suggesting a potential upside of 400.00%. OPKO Health has a consensus price target of $3.17, suggesting a potential upside of 131.14%. Given uniQure's higher probable upside, analysts clearly believe uniQure is more favorable than OPKO Health.
OPKO Health has a net margin of -31.44% compared to uniQure's net margin of -1,562.22%. OPKO Health's return on equity of -17.89% beat uniQure's return on equity.
Summary
OPKO Health beats uniQure on 10 of the 18 factors compared between the two stocks.
Get uniQure News Delivered to You Automatically
Sign up to receive the latest news and ratings for QURE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding QURE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
